606 related articles for article (PubMed ID: 26319499)
1. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
2. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
[TBL] [Abstract][Full Text] [Related]
3. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study.
Lewis JR; Barre D; Zhu K; Ivey KL; Lim EM; Hughes J; Prince RL
J Bone Miner Res; 2014 Nov; 29(11):2489-97. PubMed ID: 24825180
[TBL] [Abstract][Full Text] [Related]
4. Bone health in women with premature ovarian insufficiency/early menopause: a 23-year longitudinal analysis.
Jones AR; Enticott J; Ebeling PR; Mishra GD; Teede HT; Vincent AJ
Hum Reprod; 2024 May; 39(5):1013-1022. PubMed ID: 38396142
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
6. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Tsai CF; Chen MH; Wang YP; Chu CJ; Huang YH; Lin HC; Hou MC; Lee FY; Su TP; Lu CL
Gastroenterology; 2017 Jan; 152(1):134-141. PubMed ID: 27639806
[TBL] [Abstract][Full Text] [Related]
7. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Chen G; Ning LJ; Qin Y; Zhao B; Mei D; Li XM
J Gastroenterol Hepatol; 2021 Jan; 36(1):156-162. PubMed ID: 32542684
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.
Abrahamsen B; Vestergaard P
Bone; 2013 Nov; 57(1):269-71. PubMed ID: 23973557
[TBL] [Abstract][Full Text] [Related]
9. Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
Moberg LM; Nilsson PM; Samsioe G; Borgfeldt C
Maturitas; 2014 Aug; 78(4):310-5. PubMed ID: 24958166
[TBL] [Abstract][Full Text] [Related]
10. The relationship between proton pump inhibitor adherence and fracture risk in the elderly.
Ding J; Heller DA; Ahern FM; Brown TV
Calcif Tissue Int; 2014 Jun; 94(6):597-607. PubMed ID: 24706060
[TBL] [Abstract][Full Text] [Related]
11. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice.
McGowan B; Bennett K; Barry M
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):763-9. PubMed ID: 20582909
[TBL] [Abstract][Full Text] [Related]
12. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors.
Bahtiri E; Islami H; Hoxha R; Qorraj-Bytyqi H; Rexhepi S; Hoti K; Thaçi K; Thaçi S; Karakulak Ç
J Bone Miner Metab; 2016 Sep; 34(5):571-9. PubMed ID: 26209167
[TBL] [Abstract][Full Text] [Related]
13. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
Linton A; Bacon T; Peterson M
J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis.
Okamoto T; Hatakeyama S; Hosogoe S; Tanaka Y; Imanishi K; Takashima T; Saitoh F; Suzuki T; Ohyama C
PLoS One; 2018; 13(7):e0199160. PubMed ID: 29969455
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
McNicholl AG; Linares PM; Nyssen OP; Calvet X; Gisbert JP
Aliment Pharmacol Ther; 2012 Sep; 36(5):414-25. PubMed ID: 22803691
[TBL] [Abstract][Full Text] [Related]
16. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Kendler DL; Marin F; Geusens P; López-Romero P; Lespessailles E; Body JJ; Minisola S
Bone; 2020 Jan; 130():115113. PubMed ID: 31654779
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
Gray SL; LaCroix AZ; Larson J; Robbins J; Cauley JA; Manson JE; Chen Z
Arch Intern Med; 2010 May; 170(9):765-71. PubMed ID: 20458083
[TBL] [Abstract][Full Text] [Related]
18. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.
Gomm W; von Holt K; Thomé F; Broich K; Maier W; Fink A; Doblhammer G; Haenisch B
JAMA Neurol; 2016 Apr; 73(4):410-6. PubMed ID: 26882076
[TBL] [Abstract][Full Text] [Related]
19. The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China.
Ying J; Li LC; Wu CY; Yu ZW; Kan LD
Rev Esp Enferm Dig; 2019 Oct; 111(10):738-743. PubMed ID: 31373505
[TBL] [Abstract][Full Text] [Related]
20. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period.
Haastrup PF; Paulsen MS; Christensen RD; Søndergaard J; Hansen JM; Jarbøl DE
Aliment Pharmacol Ther; 2016 Jul; 44(1):78-87. PubMed ID: 27137875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
